Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting, 54890 [2010-22499]
Download as PDF
54890
Federal Register / Vol. 75, No. 174 / Thursday, September 9, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Suicidality: Prospective Assessment of
Occurrence in Clinical Trials.’’ The
purpose of this guidance is to assist
sponsors in prospectively assessing the
occurrence of treatment-emergent
suicidality in clinical trials of drug and
biological products. Specifically, this
guidance addresses FDA’s current
thinking regarding the importance of
suicidality assessment in psychiatric
and nonpsychiatric drug trials and the
general principles for how best to
accomplish this assessment during drug
development.
The principles discussed in this
guidance for the prospective assessment
of suicidality involve actively querying
patients about the occurrence of suicidal
thinking and behavior, rather than
relying on patients to report such
occurrences spontaneously, followed by
retrospective classification of events
into appropriate categories. This
guidance recommends a specific
suicidality assessment instrument that
can be used to conduct such prospective
assessments and offers guidance on the
use of alternative instruments. This
guidance does not address the complex
analytic issues involved in the analysis
of the suicidality data that will be
derived from prospective assessments of
suicidality; these issues will be
addressed in separate guidances.
Comments are welcome regarding the
recommended approach of carrying out
prospective suicidality assessments in
all clinical trials for all drugs that are
pharmacologically similar to
isotretinoin and other tretinoins, beta
blockers (especially those entering the
brain), reserpine, drugs for smoking
cessation, and drugs for weight loss for
which possible signals of risk for
suicidality have already been identified.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on the prospective assessment of
suicidality occurrence in clinical trials.
It does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
VerDate Mar<15>2010
17:24 Sep 08, 2010
Jkt 220001
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Dated: September 2, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–22404 Filed 9–8–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Neonatal Research
Network.
Date: October 5–6, 2010.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Legacy Hotel and Meeting Center,
1775 Rockville Pike, Rockville, MD 20852.
Contact Person: Rita Anand, PhD,
Scientific Review Officer, Division of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892,
301–496–148, anandr@mail.nih.gov.
Frm 00045
Fmt 4703
Dated: September 2, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–22499 Filed 9–8–10; 8:45 am]
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
PO 00000
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentablematerial,
and personal information concerning
individuals associated with the grant
applications,the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Aging and
Distal Radius Fracture.
Date: October 7, 2010.
Time: 6 p.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Alicja L. Markowska, PhD,
DSC, Scientific Review Branch, National
Institute on Aging, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892, 301–496–
9666, markowsa@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Aminergic
Function in Brain Aging and Alzheimer’s
Disease.
Date: October 19, 2010.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Alexander Parsadanian,
Ph.D., Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
PARSADANIANA@NIA.NIH.GOV.
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 75, Number 174 (Thursday, September 9, 2010)]
[Notices]
[Page 54890]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-22499]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; Neonatal Research Network.
Date: October 5-6, 2010.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Legacy Hotel and Meeting Center, 1775 Rockville Pike,
Rockville, MD 20852.
Contact Person: Rita Anand, PhD, Scientific Review Officer,
Division of Scientific Review, Eunice Kennedy Shriver National
Institute of Child Health and Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892, 301-496-148,
anandr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: September 2, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-22499 Filed 9-8-10; 8:45 am]
BILLING CODE 4140-01-P